Clinical Trial Update: Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis [Phase 2]

View source ↗

Summary

A Phase 2 study of exclusive hypofractionated stereotactic radiotherapy for a non-resectable single brain metastasis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastasis

Snippet

Sponsor: Barretos Cancer Hospital | Conditions: Cancer, Metastasis | Phase 2 | Status: WITHDRAWN